ARCHIVES

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

This article is from The Cancer Letter archive.

Vol. 02 No. 37 | September 10, 1976

Download PDF Visit The Full Archive

Related Articles

NDA n Vp-16 Goes to Advisory Committee Sept. 30

August 27, 1982

FDA Proposes Office For Patients With Life Threatening Disease

November 13, 1992

SPORE Eligibility, Cost Issues Clarified In Addendum To RFA

October 25, 1991

Brief: President Expected To Propose 4.7% Increase In NIH Budget; Bernard Fisher Wins Award

January 14, 1994

FDA To Issue “Complete Response” Letters To Drug Sponsors.

July 11, 2008

NCI Seeks Changes In CIS Funding Plan With Next Recompetition

April 24, 1987